192 related articles for article (PubMed ID: 32535224)
1. Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy.
Previtali SC; Gidaro T; Díaz-Manera J; Zambon A; Carnesecchi S; Roux-Lombard P; Spitali P; Signorelli M; Szigyarto CA; Johansson C; Gray J; Labolle D; Porte Thomé F; Pitchforth J; Domingos J; Muntoni F
Pharmacol Res; 2020 Sep; 159():104999. PubMed ID: 32535224
[TBL] [Abstract][Full Text] [Related]
2. Na
Bkaily G; Jacques D
Can J Physiol Pharmacol; 2017 Oct; 95(10):1213-1223. PubMed ID: 28727929
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
[TBL] [Abstract][Full Text] [Related]
4. Protective effects of rimeporide on left ventricular function in golden retriever muscular dystrophy dogs.
Ghaleh B; Barthélemy I; Wojcik J; Sambin L; Bizé A; Hittinger L; Tran TD; Thomé FP; Blot S; Su JB
Int J Cardiol; 2020 Aug; 312():89-95. PubMed ID: 32199683
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
[TBL] [Abstract][Full Text] [Related]
6. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
[TBL] [Abstract][Full Text] [Related]
7. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
8. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
9. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
[TBL] [Abstract][Full Text] [Related]
10. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy.
Moulton HM; Moulton JD
Biochim Biophys Acta; 2010 Dec; 1798(12):2296-303. PubMed ID: 20170628
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy.
Finanger E; Vandenborne K; Finkel RS; Lee Sweeney H; Tennekoon G; Yum S; Mancini M; Bista P; Nichols A; Liu H; Fretzen A; Donovan JM
J Neuromuscul Dis; 2019; 6(1):43-54. PubMed ID: 30452422
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice.
Woodcock IR; Tachas G; Desem N; Houweling PJ; Kean M; Emmanuel J; Kennedy R; Carroll K; de Valle K; Adams J; Lamandé SR; Coles C; Tiong C; Burton M; Villano D; Button P; Hogrel JY; Catling-Seyffer S; Ryan MM; Delatycki MB; Yiu EM
PLoS One; 2024; 19(1):e0294847. PubMed ID: 38271438
[TBL] [Abstract][Full Text] [Related]
14. Improvement of Duchenne muscular dystrophy phenotype following obestatin treatment.
González-Sánchez J; Sánchez-Temprano A; Cid-Díaz T; Pabst-Fernández R; Mosteiro CS; Gallego R; Nogueiras R; Casabiell X; Butler-Browne GS; Mouly V; Relova JL; Pazos Y; Camiña JP
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1063-1078. PubMed ID: 30216693
[TBL] [Abstract][Full Text] [Related]
15. Histological effects of givinostat in boys with Duchenne muscular dystrophy.
Bettica P; Petrini S; D'Oria V; D'Amico A; Catteruccia M; Pane M; Sivo S; Magri F; Brajkovic S; Messina S; Vita GL; Gatti B; Moggio M; Puri PL; Rocchetti M; De Nicolao G; Vita G; Comi GP; Bertini E; Mercuri E
Neuromuscul Disord; 2016 Oct; 26(10):643-649. PubMed ID: 27566866
[TBL] [Abstract][Full Text] [Related]
16. SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy.
Sarathy A; Wuebbles RD; Fontelonga TM; Tarchione AR; Mathews Griner LA; Heredia DJ; Nunes AM; Duan S; Brewer PD; Van Ry T; Hennig GW; Gould TW; Dulcey AE; Wang A; Xu X; Chen CZ; Hu X; Zheng W; Southall N; Ferrer M; Marugan J; Burkin DJ
Mol Ther; 2017 Jun; 25(6):1395-1407. PubMed ID: 28391962
[TBL] [Abstract][Full Text] [Related]
17. Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice.
Bonuccelli G; Sotgia F; Capozza F; Gazzerro E; Minetti C; Lisanti MP
Cell Cycle; 2007 May; 6(10):1242-8. PubMed ID: 17495527
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
[TBL] [Abstract][Full Text] [Related]
19. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function.
Hoffman EP; Schwartz BD; Mengle-Gaw LJ; Smith EC; Castro D; Mah JK; McDonald CM; Kuntz NL; Finkel RS; Guglieri M; Bushby K; Tulinius M; Nevo Y; Ryan MM; Webster R; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Siener C; Jaros M; Shale P; McCall JM; Nagaraju K; van den Anker J; Conklin LS; Cnaan A; Gordish-Dressman H; Damsker JM; Clemens PR;
Neurology; 2019 Sep; 93(13):e1312-e1323. PubMed ID: 31451516
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]